American Society of Clinical Oncology (ASCO)

TAC01-CLDN18.2 integrates TAC, Triumvira’s proprietary chimeric receptor that is intended to activate and direct T-cells against tumor cells.

Dose level 3 showed the most efficacy and has been selected for the phase 2 portion of the trial.

The chief scientific officer at Omega Therapeutics discussed the issues with other modes of therapies that OEC therapy may address.

The assistant professor at MD Anderson Cancer Center discussed progress of the phase 1/2 trial being conducted at the center.

The associate professor at Medical College of Wisconsin discussed current studies evaluating cilta-cel and ongoing research.

The chief scientific officer at Omega Therapeutics discussed the importance of understanding more about and researching epigenetics.

Mary “Nora” Disis, MD, director of University of Washington Medicine’s Cancer Vaccine institute, discussed past and current clinical trials for investigational CAR-T therapies in ovarian cancer.

Mary “Nora” Disis, MD, director of University of Washington Medicine’s Cancer Vaccine institute, discussed research she coauthored that was presented at ASCO’s 2023 conference.

Jason Westin, MD, FASCP, the director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center, discussed factors that limit patient access to treatment and a potential solution.

The director of the Medical Oncology Service at the National Cancer Institute discussed the START-001 trial.

The director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed axi-cel's safety profile and an important factor for improving access to CAR-T therapies.

Jason Westin, MD, FASCP, the director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center, discussed the implications of data he presented at ASCO’s 2023 conference.

The assistant professor at MD Anderson Cancer Center discussed new data she presented at the 2023 ASCO Meeting.

The assistant professor in the Division of Lymphoma at City of Hope discussed the potential implications of real-world data she presented at ASCO’s 2023 conference.

The director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed recent and ongoing studies that are upending the paradigm in LBCL care.

The director of University of Washington Medicine’s Cancer Vaccine institute discussed the importance of continuing to develop new CAR-T approaches in the ovarian cancer field despite initial setbacks.

The associate professor at Medical College of Wisconsin discussed new findings from the CARTITUDE-4 study.

Among 101 patients included in the efficacy analysis, the ORR was 96% and the CR rate was 74.3%.

The director of University of Washington Medicine’s Cancer Vaccine institute discussed results from a phase 1 study presented at ASCO’s 2023 conference.

The associate professor at Medical College of Wisconsin discussed the rationale for the CARTITUDE-4 study and its latest updates.

The study has enrolled 17 patients as of May 2023 and enrollment is expected to complete by the end of 2024.

New overall survival analysis data on Yescarta from ZUMA-7 were presented at the ASCO 2023 meeting.

The associate professor at University College London also discussed unmet needs that remain in r/r B-ALL and another presentation of interest at ASCO’s 2023 conference.

The professor of medicine and pediatrics at Washington University in St. Louis discussed evaluating afami-cel in the SPEARHEAD-1 trial.

Among 19 patients with r/r B-ALL included in the analysis, all 19 achieved a CR or CRi.

Safety findings were also improved when compared with the previous CARTITUDE-1 study, suggesting the therapy may be better tolerated in earlier lines of therapy.

The director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed the implications of overall survival data that he presented at ASCO’s 2023 conference.

The study began enrollment in January 2023.

Additionally, promising efficacy signals were reported—namely response rates and disease control rates—in the phase 1 clinical trial (NCT04429087) data that were presented at the 2023 ASCO Annual Meeting.

The professor of medicine and pediatrics at Washington University in St. Louis discussed updated survival data from SPEARHEAD-1.